Skip to main content

Advertisement

Table 5 Relationship between the SAA and EBV DNA pretreatment and the clinical characteristics in 304 patients with NPC

From: The prognostic value of integration of pretreatment serum amyloid A (SAA)–EBV DNA (S-D) grade in patients with nasopharyngeal carcinoma

VariablesSAA (mg/L)EBV DNA (copies/mL)S-D Grade
≤ 4.46 (n = 154)> 4.46 (n = 150)P≤ 2340 (n = 161)> 2340 (n = 143)P1 (n = 92)2 (n = 131)3 (n = 81)P
Gender
 Male1141180.3491231091.0007097650.586
 Female40323834223416
Age (years)
 ≤ 4676810.42480770.4924664470.401
 > 4678698166466734
Tumor stage
 T1–232200.09534180.066222280.050
 T3–41221301271257010973
Node stage
 N0–195730.02811850<0.001668121<0.001
 N2–359774393265060
TNM stage
 I530.01671<0.001521<0.001
 II18718713102
 III81689455527126
 IV50724280224852
Treatment
 Radiotherapy28150.04832110.003211840.003
 Chemoradiotherapy1261351291327111377